Nelson L Michael Selected Research

HIV Infections (HIV Infection)

1/2024	Impact of HLA class I functional divergence on HIV control.
10/2022	Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells.
1/2022	HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019.
1/2021	Young at risk-people in Maputo City, Mozambique, present a high willingness to participate in HIV trials: Results from an HIV vaccine preparedness cohort study.
1/2019	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
1/2019	Effect of HIV infection and antiretroviral therapy on immune cellular functions.
1/2019	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials.
12/2018	Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
1/2018	Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size.
1/2018	Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nelson L Michael Research Topics

Disease

98	Infections 01/2024 - 05/2003
35	HIV Infections (HIV Infection) 01/2024 - 12/2009
14	Disease Progression 10/2022 - 10/2002
13	Viremia 10/2021 - 01/2014
10	COVID-19 11/2023 - 01/2020
10	Vaccinia 01/2023 - 11/2010
9	Inflammation (Inflammations) 10/2021 - 01/2016
7	Acquired Immunodeficiency Syndrome (AIDS) 01/2024 - 02/2003
6	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2022 - 04/2010
5	Dengue (Dengue Fever) 01/2022 - 01/2015
4	Breakthrough Infections 01/2021 - 09/2012
4	Zika Virus Infection 01/2021 - 08/2017
4	Virus Diseases (Viral Diseases) 01/2020 - 02/2002
2	Coinfection 09/2022 - 01/2022
2	Bites and Stings (Sting) 10/2021 - 11/2017
2	Communicable Diseases (Infectious Diseases) 01/2021 - 11/2018
2	Pain (Aches) 01/2020 - 11/2017
2	Persistent Infection 12/2018 - 01/2018
1	Injection Site Reaction 11/2023
1	Noncommunicable Diseases 09/2022
1	Severe Acute Respiratory Syndrome 04/2021
1	Hearing Loss (Hearing Impairment) 01/2021
1	Hepatitis B 01/2021
1	Belonephobia 01/2021
1	Yellow Fever 12/2020
1	Tick-Borne Encephalitis (Encephalitis, Tick Borne) 12/2020
1	Japanese Encephalitis 12/2020
1	Headache (Headaches) 01/2020
1	Fatigue 01/2020
1	Fever (Fevers) 03/2019

Drug/Important Bio-Agent (IBA)

76	VaccinesIBA 11/2023 - 10/2009
28	AntibodiesIBA 01/2023 - 10/2009
16	Proteins (Proteins, Gene)FDA Link 05/2022 - 02/2002
14	RNA (Ribonucleic Acid)IBA 10/2021 - 06/2004
14	Immunoglobulin G (IgG)IBA 01/2021 - 04/2012
13	AIDS VaccinesIBA 01/2023 - 04/2011
13	AntigensIBA 01/2022 - 06/2004
9	Immunoglobulin A (IgA)IBA 12/2020 - 04/2012
8	EpitopesIBA 01/2024 - 02/2011
8	Neutralizing AntibodiesIBA 01/2023 - 01/2013
8	AIDSVAXIBA 11/2019 - 12/2009
7	DNA (Deoxyribonucleic Acid)IBA 11/2021 - 06/2007
7	Glycoproteins (Glycoprotein)IBA 01/2021 - 12/2012
7	Peptides (Polypeptides)IBA 11/2020 - 10/2009
7	AIDSVAX B-EIBA 11/2019 - 12/2009
6	Biomarkers (Surrogate Marker)IBA 09/2022 - 05/2016
6	Broadly Neutralizing AntibodiesIBA 01/2022 - 01/2017
6	CytokinesIBA 01/2021 - 06/2014
5	Antiviral Agents (Antivirals)IBA 10/2019 - 10/2002
4	HLA Antigens (Human Leukocyte Antigens)IBA 01/2024 - 11/2018
4	Interleukin-6 (Interleukin 6)IBA 10/2019 - 04/2011
3	Nucleic AcidsIBA 11/2023 - 04/2015
3	Combined VaccinesIBA 11/2023 - 01/2017
3	GP 140IBA 05/2022 - 11/2016
3	Indicators and Reagents (Reagents)IBA 01/2020 - 01/2014
3	erdosteineIBA 11/2019 - 07/2012
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2018 - 01/2017
3	ChemokinesIBA 01/2018 - 05/2009
3	MF59 oil emulsionIBA 01/2018 - 02/2015
3	Monoclonal AntibodiesIBA 02/2016 - 08/2015
2	HLA-A Antigens (HLA-A)IBA 01/2024 - 11/2010
2	HLA-B Antigens (HLA-B)IBA 01/2024 - 05/2011
2	N-acetyltalosaminuronic acid (NAT)IBA 01/2023 - 04/2015
2	Viral RNAIBA 01/2023 - 11/2021
2	aluminum sulfate (alum)IBA 05/2022 - 02/2015
2	Ferritins (Ferritin)IBA 05/2022 - 03/2021
2	COVID-19 VaccinesIBA 05/2022 - 09/2020
2	NanovaccinesIBA 05/2022 - 03/2021
2	Aluminum Hydroxide (Algeldrate)FDA Link 05/2022 - 02/2015
2	Polysaccharides (Glycans)IBA 10/2021 - 01/2016
2	Complement System Proteins (Complement)IBA 01/2021 - 01/2017
2	Lipopolysaccharide ReceptorsIBA 01/2017 - 04/2011
2	Fatty Acid-Binding ProteinsIBA 01/2017 - 05/2016
2	Liposomes (Liposome)IBA 01/2017 - 10/2009
1	N-(2-cyanoethylene)urea (BA 1)IBA 01/2023
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2023
1	DNA VaccinesIBA 01/2023
1	vesatolimodIBA 05/2022
1	saponin QA-21V1 (QS21)IBA 05/2022
1	Dihydrotachysterol (AT 10)IBA 01/2022
1	CYD-TDV vaccineIBA 01/2022
1	Dengue VaccinesIBA 01/2022
1	Angiotensin-Converting Enzyme 2IBA 12/2021
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 10/2021
1	SARS-CoV-2 spike proteinIBA 03/2021
1	N 556IBA 01/2021
1	Illicit Drugs (Recreational Drugs)IBA 01/2021
1	tapasinIBA 11/2020
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 12/2019
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 12/2019
1	Interleukin-15 (Interleukin 15)IBA 12/2019
1	NeopterinIBA 12/2019

Therapy/Procedure

15	Therapeutics 10/2022 - 10/2002
10	Art Therapy 10/2021 - 08/2014
4	Highly Active Antiretroviral Therapy (HAART) 01/2017 - 05/2003
2	Condoms (Condom) 01/2021 - 01/2019
2	Aftercare (After-Treatment) 01/2016 - 01/2015
1	Immunotherapy 01/2024
1	Contraindications 10/2023
1	Drug Therapy (Chemotherapy) 01/2022